UBS downgraded Immunovant (IMVT) to Neutral from Buy with a price target of $17, down from $38.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating
- Immunovant’s Strategic Advancements and Targeted Approach Drive Buy Rating
- Immunovant Announces New CEO Amid Strategic Shift
- Immunovant appoints Eric Venker as CEO, Girao as CFO
- Insider Moves: Cytokinetics, Bj’s, Gran Tierra, PBF, Immunovant